SUPN earnings date and last-quarter result: last quarter beat, P/E -91.79. Updated 2026-07-23.
Supernus Pharmaceuticals (SUPN) Research Hub
Supernus Pharmaceuticals (SUPN) trades on NASDAQ, US in the Healthcare (Drug Manufacturers - Specialty & Generic) sector. As of 2026-10-26, shares last closed at 40.77 USD (+0.17%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -91.79, market cap 2.74B. This hub links to the full technical, earnings and options research available for SUPN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - Specialty & Generic) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 40.77 USD (+0.17%) |
| 52-week range | 37.625 USD – 51.37 USD |
| Trend regime | Range |
| 14-day RSI | 41.7 (Bearish) |
| Trailing P/E | -91.79 |
| Market cap | 2.74B |
| Dividend yield | 0.00% |
Available research for SUPN
Covered Call on SUPN: how it works, illustrative setup around the real 40.77 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SUPN: how it works, illustrative setup around the real 40.77 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SUPN: how it works, illustrative setup around the real 40.77 USD price, max profit/loss, breakeven and when to use it. Educational.
SUPN technical analysis: range, last 40.77 USD, RSI 41.7, 52w range 37.625 USD–51.37 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is SUPN in?
Supernus Pharmaceuticals (SUPN) is classified under Healthcare (Drug Manufacturers - Specialty & Generic), listed on NASDAQ, US.
Is SUPN in an uptrend or downtrend?
As of 2026-10-26, SUPN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SUPN's trailing P/E ratio?
SUPN's trailing P/E is -91.79, with a market cap of 2.74B. See the earnings research page for full valuation detail.